What is claimed is:

1. A pharmaceutical composition comprising:

at least one compound chosen from 2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carbonyl)-4,4-dimethylpent-2-enenitrile and pharmaceutically acceptable salts thereof; and

0.1 ± 0.005% to 4 ± 0.2% by weight of at least one pH dependent gelling agent, wherein the at least one pH dependent gelling agent is Carbopol® 980 polymer;

0.1 ± 0.005% to 65 ± 3.25% by weight of at least one emollient or humectant, wherein the at least one emollient or humectant is chosen from glycerin, propylene glycol, and combinations thereof;

0.01 ± 0.005% to 0.7 ± 0.035% by weight of at least one preservative, wherein the at least one preservative is chosen from methylparaben, propylparaben, and combinations thereof;

0.1 ± 0.005% to 20 ± 1% by weight of at least one lubricity agent, wherein the at least one lubricity agent is chosen from medium chain triglycerides;

0.1 ± 0.005% to 20 ± 1% by weight of at least one wetting agent, wherein the at least one wetting agent is polysorbate 80; and

at least one vehicle;

wherein the pharmaceutical composition is in the form of a gel.

2. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises:

0.1 ± 0.005% to 20 ± 1% by weight of medium chain triglycerides;

0.1 ± 0.005% to 20 ± 1% by weight of Polysorbate 80;

0.1 ± 0.005% to 20 ± 1% by weight of glycerin;

0.1 ± 0.005% to 45 ± 2.25% by weight of propylene glycol;

0.01 ± 0.0005% to 0.5 ± 0.025% by weight of methylparaben;

0.01 ± 0.0005% to 0.2 ± 0.01% by weight of propylparaben;

0.1 ± 0.005% to 4% ± 0.2 by weight of Carbopol® 980 polymer;

an amount of 10% (w/w) sodium hydroxide solution sufficient to adjust the pH of the pharmaceutical composition to a value in the range of 4 ± 0.2 to about 6 ± 0.3; and

Q.S. to 100 of purified water.

3. A pharmaceutical composition comprising:

at least one compound chosen from 2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carbonyl)-4,4-dimethylpent-2-enenitrile and pharmaceutically acceptable salts thereof; and

at least one saturated hydrocarbon, wherein the at least one saturated hydrocarbon is chosen from mineral oil, hydrogenated castor oil, and combinations thereof;

0.1 ± 0.005% to 20 ± 1% by weight of at least one viscosity modifier, wherein the at least one viscosity modifier is microcrystalline wax;

0.01 ± 0.0005% to 30 ± 1.5% by weight of at least one dispersing agent, wherein the at least one dispersing agent is chosen from dimethicone, medium chain triglycerides, and combinations thereof;

wherein the pharmaceutical composition is in the form of an ointment.

4. The pharmaceutical composition of claim 3, wherein the at least one compound is suspended in the ointment.

5. The pharmaceutical composition of claim 3, wherein the pharmaceutical composition comprises:

0.1 ± 0.005% to 20 ± 1% by weight of medium chain triglycerides;

0.1 ± 0.005% to 20 ± 1% by weight of microcrystalline wax;

0.1 ± 0.005% to 10 ± 0.5% by weight of hydrogenated castor oil;

0.01 ± 0.0005% to 10 ± 0.5% by weight of dimethicone; and

Q.S. to 100 of white mineral oil.

6. A pharmaceutical composition comprising:

at least one compound chosen from 2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carbonyl)-4,4-dimethylpent-2-enenitrile and pharmaceutically acceptable salts thereof; and

1 ± 0.05% to 45 ± 2.25% by weight of at least one dissolution agent, wherein the at least one dissolution agent is oleic acid;

0.1 ± 0.005% to 5 ± 0.25% by weight of at least one gelling-emulsifier, wherein the at least one gelling-emulsifier is Pemulen^{TM} TR-1;

0.1 ± 0.005% to 5 ± 0.25% by weight of at least one alcohol;

0.1 ± 0.005% to 65 ± 3.25% by weight of at least one emollient or humectant, wherein the at least one emollient or humectant is chosen from glycerin, propylene glycol, and combinations thereof; and

at least one vehicle;

wherein the pharmaceutical composition is in the form of a cream.

7. The pharmaceutical composition of claim 6, wherein the at least one compound is dissolved in the cream.

8. The pharmaceutical composition of claim 6, wherein the pharmaceutical composition comprises:

1 ± 0.05% to 45 ± 2.25% by weight of oleic acid;

0.1 ± 0.005% to 20 ± 1% by weight of glycerin;

0.1 ± 0.005% to 45 ± 2.25% by weight of propylene glycol;

0.1 ± 0.005% to 5 ± 0.25% by weight of benzyl alcohol;

0.1 ± 0.005% to 5 ± 0.25% by weight of a Pemulen^{TM} polymer;

an amount of 10% (w/w) sodium hydroxide solution sufficient to adjust the pH to a value in the range of 4 ± 0.2 to about 6 ± 0.3; and

Q.S. to 100 of purified water.

9. The pharmaceutical composition of any one of claims 1-8, wherein the pharmaceutical composition comprises 0.1 ± 0.005% to 10 ± 0.5% by weight of the at least one compound.

10. The pharmaceutical composition of any one of claims 1-9, wherein the pharmaceutical composition comprises at least 0.5 ± 0.025% by weight of the at least one compound.

11. The pharmaceutical composition of any one of claims 1-10, wherein the pharmaceutical composition comprises 1 ± 0.05% by weight of the at least one compound.

12. The pharmaceutical composition of any one of claims 1-10, wherein the pharmaceutical composition comprises 2 ± 0.1% by weight of the at least one compound.

13. The pharmaceutical composition of any one of claims 1-12, wherein at least 95 ± 4.75% by weight of the at least one compound is (R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carbonyl)-4,4-dimethylpent-2-enenitrile.

14. The pharmaceutical composition of any one of claims 1-13, wherein at least 95 ± 4.75% by weight of the at least one compound is an (E) isomer.

15. The pharmaceutical composition of claim 13 or 14, wherein the at least one compound is substantially amorphous.

16. The pharmaceutical composition of any one of claims 13-15, wherein the at least one compound is micronized.

17. The pharmaceutical composition of claim 16, wherein the at least one compound has a particle size distribution D_{90} in the range of 5 ± 0.25 to 10 ± 0.5 microns.

18. The pharmaceutical composition of any one of claims 1-14, wherein the at least one compound is crystalline.

19. The pharmaceutical composition of claim 18, wherein the at least one compound is crystalline Form (I) characterized by an X-ray powder diffractogram having a signal at least three two-theta values chosen from 6.3 ± 0.2, 12.6 ± 0.2, 16.2 ± 0.2, 17.6 ± 0.2, 18.2 ± 0.2, 18.4 ± 0.2, and 22.1 ± 0.2.

20. The pharmaceutical composition of claim 18, wherein the at least one compound is crystalline Form (II) characterized by an X-ray powder diffractogram having a signal at least three two-theta values chosen from 6.3 ± 0.2, 15.2 ± 0.2, 16.0 ± 0.2, 16.6 ± 0.2, 17.7 ± 0.2, 20.0 ± 0.2, 24.8 ± 0.2, and 27.5 ± 0.2.

21. Use of at least one topical pharmaceutical composition of any one of claims 1-19 in the manufacture of a medicament for treating a dermatological disorder in a mammal in need

thereof, wherein the composition is to be topically administered to at least a portion of the skin of the mammal.

22. The use of claim 21, wherein the dermatological disorder is chosen from pemphigus vulgaris, pemphigus foliaceus, cutaneous lupus, cutaneous lupus erythematosus, dermatitis, discoid lupus, atopic dermatitis, bullous pemphigoid, drug related skin reaction, chronic idiopathic urticaria, chronic spontaneous urticaria, symptomatic dermographism, alopecia, alopecia areata, vitiligo, pyoderma gangrenosum, membrane pemphigoid, epidermolysis bullosa acquisita, Steven Johnson Syndrome, TEN Toxic epidermal necrolysis, drug eruptions, folliculitis decalvans, pseudofolliculitis barbae, leukocytoclastic vasculitis, hidradenitis suppurativa, palmar plantar pustulosis, Lichenoid dermatitis, dermatitis herpetiformis, rosacea, erythema of rosacea, papulopustular rosacea, neutrophilic dermatoses, chronic kidney disease associated pruritis, end stage renal disease induced pruritis, acne, mycosis fungoides, and sweet syndrome in a mammal in need thereof.

23. The use of claim 21 or 22, wherein the dermatological disorder is pemphigus vulgaris or pemphigus foliaceus.

24. The use of claim 21 or 22, wherein the dermatological disorder is atopic dermatitis.

25. The use of claim 21 or 22, wherein the mammal is a human.